From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.

Bell Direct
March 20, 2026

In this episode of From the Helm, Grady chats with Alterity Therapeutics (ASX:ATH) CEO David Stamler, to discuss their neurodegenerative disorder treatment specifically targeting Multiple System Atrophy (MSA), a rare and aggressive disease affecting involuntary functions and motor control.

How to open an account

Bell Direct
September 1, 2015

Beston Global Food Company Interview

Bell Direct
August 28, 2015

Bell Direct Insights: Richard Hemming

Bell Direct
August 24, 2015

Bell Potter video: Bank sector update

Bell Direct
August 14, 2015

Agricultural Sector Review

Bell Direct
August 3, 2015

Peter Quinton: three REITs

Bell Direct
July 23, 2015

Contango CIO interview

Bell Direct
July 17, 2015

Julia Lee on mFunds

Bell Direct
July 6, 2015